VETCO PHARMACEUTICAL INC.
Update：2026/09/15
Industries
Main Industry
Health Care
Main Product/Service
Antican® Pet Cancer Medication. In Taiwan, the approved indication for Antican® is canine perianal gland adenoma (Veterinary Drug License No. 09176), and it is administered via intratumoral injection. After injection, the drug acts directly on cancer cells. During administration, only simple restraint of the dog is required, with no anesthesia needed, and it is free from the side effects of traditional chemotherapy drugs.
(The content above was translated by AI.)
(The content above was translated by AI.)
Founded Year
2012
Unified Business No.
53742349
Status
Closed
Number of Employees
0
Total Paid-in
Capital
160,009,540 (NT$)
Location of Company
Taiwan
, New Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Since its establishment in 2012, Vetco Pharmaceuticals has focused on the research and development of innovative drugs. Its "Antican®" is Asia's first cancer treatment drug for pets, and is also one of the few successfully developed animal cancer drugs in the world.
Vetco Pharmaceuticals is a pioneer in animal cancer drugs. Chairman Chen Chien-hung brought R&D technology back to invest in Taiwan, continuously opening up brand-new industrial markets, making Vetco Pharmaceuticals one of the few biotechnology companies in Taiwan targeting the animal market. Upholding the core values of technology, professionalism, safety, and efficacy, Vetco Pharmaceuticals has assembled an outstanding R&D team for independent research and development, providing comprehensive solutions for animal healthcare.
Under the mission of innovatively developing new animal drugs, assisting veterinarians in exercising their expertise, and improving the quality of life for owners and animals, Vetco Pharmaceuticals is market-demand-oriented. Coupled with patented technologies, the company possesses rich experience ranging from drug R&D to clinical trials, creating sustainable corporate value through continuous innovation and breakthroughs.
Vetco Pharmaceuticals has obtained the qualification of a new drug biotechnology company from the Ministry of Economic Affairs and received subsidies from the Leading New Product Project. Since its establishment, it has been recommended multiple times by the Council of Agriculture, Executive Yuan, to represent Taiwan at the North American Biotechnology Industry Exhibition, and has been recognized with the Council of Agriculture's Scientific and Technological Agricultural Enterprise Innovation Award, as well as the Bronze Award in the Taiwan Biomedical and New Agriculture Industry Selection by the Epoch Foundation.
(The content above was translated by AI.)
Vetco Pharmaceuticals is a pioneer in animal cancer drugs. Chairman Chen Chien-hung brought R&D technology back to invest in Taiwan, continuously opening up brand-new industrial markets, making Vetco Pharmaceuticals one of the few biotechnology companies in Taiwan targeting the animal market. Upholding the core values of technology, professionalism, safety, and efficacy, Vetco Pharmaceuticals has assembled an outstanding R&D team for independent research and development, providing comprehensive solutions for animal healthcare.
Under the mission of innovatively developing new animal drugs, assisting veterinarians in exercising their expertise, and improving the quality of life for owners and animals, Vetco Pharmaceuticals is market-demand-oriented. Coupled with patented technologies, the company possesses rich experience ranging from drug R&D to clinical trials, creating sustainable corporate value through continuous innovation and breakthroughs.
Vetco Pharmaceuticals has obtained the qualification of a new drug biotechnology company from the Ministry of Economic Affairs and received subsidies from the Leading New Product Project. Since its establishment, it has been recommended multiple times by the Council of Agriculture, Executive Yuan, to represent Taiwan at the North American Biotechnology Industry Exhibition, and has been recognized with the Council of Agriculture's Scientific and Technological Agricultural Enterprise Innovation Award, as well as the Bronze Award in the Taiwan Biomedical and New Agriculture Industry Selection by the Epoch Foundation.
(The content above was translated by AI.)
